Skip to main content

Wellbutrin XL

(bupropion hydrochloride)

Wellbutrin XL (bupropion hydrochloride); not controlled

Full Prescribing Information DailyMed Drug Information

Summary

Wellbutrin XL is an aminoketone antidepressant supplied as a once-daily extended-release tablet, approved for major depressive disorder and for prevention of seasonal affective disorder in adults. It has no pediatric indication at any age, so every use in a child or adolescent is off-label. Among antidepressants it is distinctive for no serotonergic action and no sexual dysfunction or weight gain, at the cost of a dose-related seizure risk. Not controlled; brand and generic.

Forms & Strengths

  • Extended-release (XL) tablets: 150 mg, 300 mg, the only two XL strengths
  • Sustained-release (SR) tablets: 100 mg, 150 mg, 200 mg, dosed twice daily
  • Immediate-release tablets: 75 mg, 100 mg, dosed three times daily
  • Separate NDAs: Forfivo XL 450 mg; Aplenzin (hydrobromide) 174 mg, 348 mg, 522 mg
  • Combination products: dextromethorphan-bupropion (Auvelity); naltrexone-bupropion (Contrave)

Dosing

  • Age: adults only. No pediatric indication at any age and no pediatric ADHD indication at any age; any use in a young person is off-label.
  • Onset: 1 to 2 weeks for early effect; 4 to 6 weeks for full response
  • Duration: continuous with once-daily dosing; bupropion half-life 21 hours, hydroxybupropion about 20 hours
  • Release Profile: once-daily matrix tablet, bioequivalent over 24 hours to immediate-release 100 mg three times daily
  • Initial Dose: 150 mg once daily, for both approved indications
  • Titration:
    • Major depressive disorder: may increase to 300 mg once daily after 4 days
    • Seasonal affective disorder: may increase to 300 mg once daily after 1 week
    • Increase gradually; abrupt escalation raises the seizure risk
  • Max Dose: 300 mg/day. The 450 mg ceiling belongs to Forfivo XL, a different product
  • Considerations: Moderate to severe hepatic impairment caps the dose at 150 mg every other day; mild impairment or GFR under 90 mL/min needs a reduced dose or frequency.

Pharmacology

  • Mechanism: norepinephrine-dopamine reuptake inhibitor; no serotonin reuptake or monoamine oxidase inhibition
  • Metabolism: CYP2B6 to hydroxybupropion, the principal active metabolite. Renal excretion of metabolites means impairment causes accumulation
  • Class Positioning: chosen for the absent serotonergic action: no sexual dysfunction, appetite suppression rather than weight gain. Approved non-stimulant alternatives are Strattera and Qelbree

Indications

  • Major Depressive Disorder (ICD-10: F32.x, F33.x): adults only
  • Seasonal Affective Disorder, prevention (ICD-10: F33.x seasonal pattern): adults only. Start in autumn, continue through winter
  • No pediatric indication at any age, and specifically no pediatric ADHD indication

Off-Label Uses

  • ADHD in children and adolescents (ICD-10: F90.x): limited data. Second-line where a stimulant is not tolerated and depression coexists.
    • The label carries no ADHD indication and no ADHD trial.
    • AHRQ found medication improves ADHD symptoms overall but graded no bupropion-specific pediatric evidence. (AHRQ 2024)
    • Weigh the seizure risk against the two approved non-stimulants first.
  • Pediatric major depressive disorder (ICD-10: F32.x, F33.x): insufficient; the adult indication does not extend downward.
  • Adolescent smoking or vaping cessation (ICD-10: F17.2x): insufficient. The label's neuropsychiatric warning applies at any age.
  • Any use in a patient with an eating disorder (ICD-10: F50.x): contraindicated, not merely unsupported.

Contraindications & Warnings

  • Boxed Warning: SUICIDAL THOUGHTS AND BEHAVIORS. Antidepressants increased suicidal thinking and behaviour in children, adolescents and young adults. Monitor for worsening and emergent suicidality, including in off-label pediatric use.
  • Contraindicated:
    • Seizure disorder.
    • Current or prior bulimia or anorexia nervosa; absolute, and easily missed in an adolescent.
    • Abrupt discontinuation of alcohol, benzodiazepines, barbiturates or antiepileptics; withdrawal lowers the seizure threshold.
    • Concomitant MAOI, or use within 14 days of stopping one; initiation on linezolid or intravenous methylene blue.
    • Known hypersensitivity to bupropion or any other ingredient.
  • Use with caution:
    • Conditions lowering the seizure threshold: severe head injury, arteriovenous malformation, CNS tumour or infection, stroke, hypoglycemia, hyponatremia, hypoxia.
    • Never co-prescribe two bupropion products, and see Drug Interactions for other threshold-lowering drugs.
    • Insulin- or oral-hypoglycemic-treated diabetes, and anorectic drugs; both predispose to seizure.
    • Pre-existing hypertension, because bupropion raises blood pressure.
    • Bipolar disorder or risk factors: activation of mania or hypomania.
    • Untreated anatomically narrow angles: angle-closure glaucoma.
    • Renal impairment below GFR 90 mL/min; active metabolites accumulate.
  • Screen before starting:
    • Seizure and head injury history, and any eating disorder. Ask the adolescent alone; bulimia is rarely volunteered.
    • Current alcohol, benzodiazepine or antiepileptic use, and any plan to stop.
    • Personal and family history of bipolar disorder or mania.
    • Blood pressure, measured before initiation.
    • Medication list for MAOIs, other bupropion products, seizure-threshold drugs.
    • Hepatic and renal function where impairment is plausible; both change the dose.

Drug Interactions

  • MAOIs (phenelzine, tranylcypromine, linezolid, intravenous methylene blue): hypertensive reactions. Contraindicated; allow 14 days in either direction.
  • CYP2D6 substrates (venlafaxine, nortriptyline, paroxetine, fluoxetine, risperidone, metoprolol, flecainide, atomoxetine): bupropion raises exposure. Reduce the substrate dose.
  • CYP2B6 inducers (ritonavir, efavirenz, carbamazepine, phenytoin): exposure falls. An increase may be needed, never above 300 mg/day.
  • CYP2B6 inhibitors (ticlopidine, clopidogrel): bupropion exposure rises 38% to 85%. Adjust on clinical response.
  • Seizure-threshold drugs (other bupropion products, antipsychotics, tricyclics, theophylline, corticosteroids, tramadol): additive risk. Avoid, or hold at 150 mg/day.
  • Levodopa and amantadine: CNS toxicity. Use lower doses.
  • Urine drug screens: false-positive for amphetamines. Confirm before treating a positive as diversion of a prescribed amphetamine (Adderall).

Administration

  • Give once daily in the morning to limit early insomnia.
  • Swallow whole; breaking the matrix converts a daily dose into an immediate-release bolus.
  • An intact tablet shell in the stool is expected, not a missed dose.
  • Never escalate faster than the label allows: 4 days to 300 mg for depression, 1 week for SAD.
  • Switching from immediate-release or SR: same total daily dose as one XL dose; confirm the product.
  • For seasonal affective disorder, start in autumn, continue through winter, taper in early spring.
  • Do not stop abruptly from 300 mg. See Discontinuation & Taper.

Side Effects

  • Common (at least 5% and twice placebo): dry mouth, nausea, insomnia, dizziness, abdominal pain, agitation, anxiety, tremor, palpitation, sweating, anorexia, rash
  • Serious:
    • Suicidal thoughts and behaviour: the boxed warning.
    • Seizure, dose-related: about 0.1% up to 300 mg/day sustained-release, about 0.4% at 300 to 450 mg/day immediate-release. Discontinue permanently.
    • Serious neuropsychiatric events during smoking cessation: depression, mania, psychosis, hallucinations, aggression, agitation, panic.
    • Hypertension.
    • Activation of mania or hypomania: stop and reassess the diagnosis.
    • Angle-closure glaucoma: sudden eye pain, redness or visual change needs same-day ophthalmology.
    • Hypersensitivity, including serum-sickness-like reactions.

Monitoring & Labs

  • Suicidality: weekly for 4 weeks, every visit through 3 months, every dose change, then each routine visit.
  • Blood pressure: baseline, 4 weeks, every dose change, then every 3 months.
  • Seizure risk review: at every dose increase and at least every 6 months. Re-ask about threshold-lowering drugs, alcohol or benzodiazepine use, and disordered eating.
  • Weight and appetite: baseline and every 3 months. Unexplained loss prompts a direct question about disordered eating.
  • Psychiatric: ask about mania, agitation, anxiety and insomnia each visit during titration, then every 3 months.
  • Renal and hepatic function: no routine schedule; recheck when circumstances change.
  • Urine drug screens: confirm any positive amphetamine result rather than acting on the immunoassay.

Discontinuation & Taper

  • Taper before stopping: from 300 mg once daily, decrease to 150 mg once daily before discontinuation.
  • Discontinue permanently and never restart if a seizure occurs.
  • Stop and seek review for serious neuropsychiatric symptoms.
  • Drug holidays are not appropriate; the effect depends on continuous exposure.
  • For seasonal affective disorder, taper in early spring rather than continuing year-round.

Pregnancy & Lactation

  • Pregnancy: first-trimester studies show no increased risk of congenital malformations overall.
    • Registry cardiovascular malformation rate 1.3% against a roughly 1% background; cardiac findings are inconsistent.
    • Background risk is 2 to 4% for birth defects, 15 to 20% for miscarriage; weigh continuation against relapse.
  • Lactation: maternal doses up to 300 mg daily give low milk levels. Case reports describe possible seizure in partially breastfed 6-month-olds; prefer another agent for a newborn. (LactMed 2026)
  • Exposure Registry: National Pregnancy Registry for Antidepressants, 1-844-405-6185, womensmentalhealth.org

Counseling Points

  • Counsel the family on:

    • This being an adult medication used off-label, with no pediatric dose ladder.
    • Never taking two bupropion products; the drug is sold under several brands.
    • Swallowing the tablet whole; an empty shell in the stool is normal.
    • Insomnia and jitteriness in the first weeks, fixed by morning dosing.
    • Telling any clinician ordering a urine drug test, because it reads as amphetamine.
    • Stepping the dose down before stopping rather than stopping outright.

  • Advise them to call for:

    • Any seizure, including a staring spell or single whole-body jerk; stop and call the same day.
    • New or worsening talk of self-harm, or a sudden mood change.
    • A burst of high energy, reduced need for sleep, or racing speech.
    • Hearing or seeing things that are not there, or new suspiciousness.
    • Sudden eye pain, redness or blurred vision.
    • Rash, hives, facial or tongue swelling, or joint pains with fever.
    • Any plan to stop alcohol, a benzodiazepine, or a seizure medicine abruptly.

References

  1. DailyMed. Wellbutrin XL (bupropion hydrochloride extended-release tablets) prescribing information. 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a435da9d-f6e8-4ddc-897d-8cd2bf777b21
  2. LactMed. Bupropion. Drugs and Lactation Database, National Institute of Child Health and Human Development. 2026. https://www.ncbi.nlm.nih.gov/books/NBK501184/
  3. AHRQ. ADHD diagnosis and treatment in children and adolescents. Comparative Effectiveness Review No. 267. 2024. https://www.ncbi.nlm.nih.gov/books/NBK603001/
  4. FDA. National Drug Code Directory, openFDA. Queried by generic name bupropion. 2026. https://api.fda.gov/drug/ndc.json?search=generic_name:%22bupropion%22&limit=1000
Back to top